A single blood-based test that measures several tau biomarkers enabled biological staging of Alzheimer’s disease. This approach not only indicated how advanced the disease was but also helped to predict its progression. This blood-based test could be highly valuable for patient management and for identifying individuals who are most likely to benefit from targeted therapies.
